LONDRES–(BUSINESS WIRE)–ViiV Healthcare, compañía global especializada en VIH de propiedad mayoritaria de GSK, con Pfizer Inc. y Shionogi Limited como accionistas, ha anunciado hoy la presentación de una solicitud de autorización de comercialización …
Author: Business Wire
Samenvatting: ViiV Healthcare dient wettelijke aanvraag in bij Europees Geneesmiddelenbureau voor onderzoek naar cabotegravir voor gebruik in combinatie met rilpivirine als de eerste maandelijkse, injecteerbare behandeling voor HIV
LONDEN–(BUSINESS WIRE)–ViiV Healthcare, het wereldwijde gespecialiseerde HIV-bedrijf dat voor het grootste deel eigendom is van GSK, met Pfizer Inc. en Shionogi Limited als aandeelhouders, heeft vandaag aangekondigd een aanvraag voor een vergunning v…
NovaBay Pharmaceuticals Reports 2019 Second Quarter Net Sales of $1.8 Million
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports net sales of $1.8 million for the three months ended Ju…
ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational Cabotegravir to Be Used in Combination With Rilpivirine as the First Monthly, Injectable Treatment for HIV
LONDON–(BUSINESS WIRE)–ViiV HC submits application to EMA for investigational cabotegravir used with rilpivirine as the first monthly, injectable treatment for HIV
慈善家Tej Kohli承諾捐贈200萬美元支持生物科技解決方案，目標是至2030年在全球杜絕角膜失明
倫敦和波士頓–(BUSINESS WIRE)–(美國商業資訊) — Tej Kohli是倫敦的一位億萬富翁，在網際網路繁榮時代因銷售電子商務支付軟體而致富，他承諾為波士頓的麻省耳眼醫院提供200萬美元，以資助治癒角膜失明的創新研究，包括開發有前景的生物科技解決方案。該善舉反映了Kohli的信念，即新科技可望創造更美好的世界，而他也在尋求不依賴移植而杜絕可避免之角膜失明的解決方案。 Kohli的全球使命是至2030年在全球根治可避免的角膜失明，該使命已取得實質性的進展。慈善性質的海德拉巴Tej …
慈善家Tej Kohli承诺捐赠200万美元支持生物技术解决方案，目标是至2030年在全球杜绝角膜失明
伦敦和波士顿–(BUSINESS WIRE)–(美国商业资讯) — Tej Kohli是伦敦的一位亿万富翁，在互联网繁荣时代，通过销售电子商务支付软件致富，他承诺向波士顿的马萨诸塞州眼耳医院提供200万美元，以资助治愈角膜失明的创新研究，包括开发有前景的生物技术解决方案。该善举反映了Kohli的信念，即新技术有望创造更美好的世界，而他也在寻求一种不依赖于移植而杜绝可避免角膜失明的解决方案。 Kohli的全球使命是至2030年在全球根治可避免角膜失明，该使命已取得了实质性的进步。慈善性质的海德拉…
Philanthropist Tej Kohli Pledges $2 Million Gift to Champion Biotech Solutions for Eliminating Corneal Blindness Worldwide By 2030
LONDON & BOSTON–(BUSINESS WIRE)–Tej Kohli, a London-based billionaire who made his fortune during the dotcom boom selling e-commerce payments software, has pledged $2 million to Massachusetts Eye and Ear in Boston to fund innovation in research t…
慈善活動家のテジ・コーリ氏が2030年までに世界で角膜失明を根絶するためのバイオテクノロジーソリューションを支えるべく200万ドルの寄付を約束
ロンドン & ボストン–(BUSINESS WIRE)–（ビジネスワイヤ） — ロンドンを拠点とする億万長者で、ドットコムブームの間に電子商取引決済ソフトウエアを販売して富みを築いたテジ・コーリ氏は、ボストンのマサチューセッツ眼耳鼻科病院への200万ドルの寄付を約束しました。これは有望なバイオテクノロジーソリューションの開発を含め、角膜失明を治療するための革新的研究を助成することが目的です。コーリ氏は回避可能な角膜失明を根絶すべく、移植に依存しないソリューションの発見を追求しており、今…
Filantropo Tej Kohli oferece US$ 2 milhões para patrocinar soluções biotecnológicas para eliminar a cegueira da córnea em todo o mundo até 2030
LONDRES E BOSTON–(BUSINESS WIRE)–Tej Kohli, um bilionário londrino que fez fortuna durante o boom do comércio digital, doou US$ 2 milhões para a Massachusetts Eye and Ear em Boston para financiar a inovação em pesquisa para curar a cegueira da córnea…
El filántropo Tej Kohli promete una donación $2 millones a las soluciones biotecnológicas ganadoras en concepto de la eliminación de la ceguera corneal a nivel mundial para el 2030
LONDRES Y BOSTON–(BUSINESS WIRE)–Tej Kohli, un multimillonario en Londres que hizo su fortuna vendiendo software para pagos online (de e-commerce), prometió $2 millones a Massachusetts Eye and Ear en Boston para financiar la innovación en investigaci…
Philanthrop Tej Kohli spendet 2 Millionen Dollar für die weltweite Förderung von Biotechnologielösungen zur Beseitigung der hornhautbedingten Erblindung bis 2030
LONDON & BOSTON–(BUSINESS WIRE)–Tej Kohli, Milliardär aus London, der sein Vermögen mit dem Verkauf von Zahlungssoftware für den elektronischen Handel während des Dotcom-Booms aufbaute, beabsichtigt mit seiner Spende von 2 Millionen US-Dollar an …
Il filantropo Tej Kohli si impegna a donare 2 milioni di dollari a sostegno delle soluzioni biotech, per estirpare la cecità corneale entro il 2030
LONDRA & BOSTON–(BUSINESS WIRE)–Tej Kohli, il miliardario londinese che ha fatto fortuna nel periodo d’oro del segmento dotcom grazie al software per i pagamenti dedicati all’e-commerce, si è impegnato a donare 2 milioni di dollari USA al Massachusetts Eye and Ear di Boston per finanziare l’innovazione nella ricerca volta alla cura della cecità corneale, incluso lo sviluppo di promettenti soluzioni biotecnologiche. La decisione riflette la filosofia di Kohli, secondo cui le nuove tecnologie p
Samenvatting: Filantroop Tej Kohli belooft 2 miljoen dollar als geschenk aan een kampioen biotechoplossingen om Corneale blindheid voor 2030 te overwinnen
LONDEN & BOSTON–(BUSINESS WIRE)–Tej Kohli, een in Londen gevestigde miljardair die zijn fortuin verdiende tijdens de dotcom-boom in de verkoop van e-commerce betaalsoftware, heeft zich ertoe verbonden 2 miljoen dollar te investeren in Massachuset…
Le philanthrope Tej Kohli annonce un don de deux millions de dollars pour promouvoir les solutions biotechnologiques qui effaceront la cécité cornéenne au niveau mondial à l'horizon 2030
LONDRES & BOSTON–(BUSINESS WIRE)–Tej Kohli, un milliardaire basé à Londres qui a fait fortune durant le boom du dot-com en vendant des logiciels de paiements d’e-commerce, vient de donner deux millions de dollars au Massachusetts Eye and Ear (Boston) pour financer l’innovation et la recherche sur la cécité cornéenne, y compris le développement de solutions biotechnologiques prometteuses. Pour M. Kohli, ce don illustre le potentiel des nouvelles technologies à construire un monde meilleur, et
Global Ophthalmology Drugs Market Report 2019 with Profiles of Novartis, F. Hoffmann-La Roche, Allergan, Valeant Pharmaceuticals, Bayer – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drugs Global Market Report 2019” report has been added to ResearchAndMarkets.com’s offering. Global Ophthalmology Drugs Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global ophthalmology drugs market. Where is the largest and fastest growing market for the ophthalmology drugs? How does the market relate to the overall economy, demography and other similar markets? Wha
Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
BEDFORD, Mass.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX…
IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced that it will report its second quarter 2019 financial and operating results on Thursday, August 1, 2019.
Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Aura Biosciences to Present Long-Term Clinical Data for AU-011 at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences to present two-year clinical data of AU-011 at ASRS.
Oyster Point Pharma Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Disease
PRINCETON, N.J.–(BUSINESS WIRE)–Oyster Point Pharma announces the enrollment of the first subject in the company’s Phase 3 clinical trial of its Nasal Spray for dry eye disease.